The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study

Cancer Management and Research
Wei JinLi Feng

Abstract

Immunotherapy provided with checkpoint inhibitors such as the programmed cell death-1 (PD-1) receptor or its ligand-1 (PD-L1) protein has been shown to be effective for treating several types of cancer, and was recently approved for use in treating malignant melanoma, advanced non-small cell lung cancer (NSCLC), urothelial carcinoma, head and neck squamous cell carcinoma, liver cancer, and additional forms of cancer. However, there is little evidence concerning its effectiveness in treating thymic squamous cell carcinoma (TSCC). Here, we report two cases of refractory TSCC that were treated with PD-1 single/combination therapy in a clinical setting. The patients exhibited variable responses to therapy without any serious adverse events. In summary, our findings show that immunotherapy provided with an immuno-checkpoint inhibitor in combination with chemotherapy/anti-angiogenesis therapy can improve the treatment response of patients with refractory TSCC. Anti-PD-1 single/combination therapy may be used as a strategy for treating advanced refractory TC.

References

Feb 15, 1991·Cancer·S Suster, J Rosai
Oct 1, 1982·The American Journal of Surgical Pathology·M R WickP E Bernatz
Jul 11, 2001·Immunologic Research·J E Ohm, D P Carbone
Sep 10, 2003·The Annals of Thoracic Surgery·Kazuya Kondo, Yasumasa Monden
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Girum L LemmaPatrick J Loehrer
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Nov 13, 2012·The Annals of Thoracic Surgery·Benny WekslerPeter F Ferson
Nov 18, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sukhmani K PaddaHeather A Wakelee
Nov 19, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F HiraiUNKNOWN West Japan Oncology Group
Nov 26, 2014·Journal of the National Cancer Institute·Ken Garber
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Mar 24, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yuki KatsuyaKoji Tsuta
Aug 12, 2016·The Lancet Oncology·Wan-Ling TanDaniel S W Tan
Aug 28, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yuki KatsuyaYuichiro Ohe
Dec 22, 2016·Immunology and Cell Biology·Kyohei Nakamura, Mark J Smyth
Feb 6, 2018·The Lancet Oncology·Giuseppe GiacconeJustine N McCutcheon
Jun 16, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jinhyun ChoMyung-Ju Ahn
Nov 30, 2018·Case Reports in Oncology·Takuma IsshikiSakae Homma
Mar 13, 2019·Immunotherapy·Yue SongMingzhi Zhang
Mar 10, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shirish GadgeelMarina C Garassino

❮ Previous
Next ❯

Citations

Apr 4, 2021·Cancers·Kyoichi KairaHiroshi Kagamu

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.